Literature DB >> 8760295

Anti-oncogenic effects of tropomyosin: isoform specificity and importance of protein coding sequences.

R H Braverman1, H L Cooper, H S Lee, G L Prasad.   

Abstract

Suppression of muscle type isoforms of tropomyosin (TM) is a common biochemical event in malignantly transformed cells. To evaluate the role of TM proteins and isoform specificity in cellular transformation, cDNAs that consist of coding sequences of TM1 (product of beta gene) and TM2 (product of alpha gene), but lacking untranslated regions (UTRs), have been expressed separately in DT (v-Ki-ras transformed NIH3T3) cells, and elevated levels of the corresponding proteins were detected. DT cells which over express TM2 manifest growth in soft agar. Elevated levels of TM1 protein in DT cells resulted in flattened cell morphology and complete abolition of anchorage independent growth. Tumorigenesis in athymic nude mice was observed in the absence of transduced TM1 mRNA. Thus, expression of TM1 protein is sufficient for tumor suppression: the UTRs of TM1 are not required for the tumor suppressive effects. Expression of TM2 protein, on the other hand, has no effect on the transformed phenotype of DT cells. These data indicate that isoforms 1 and 2 of TMs perform distinct physiological roles.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8760295

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  Post-transcriptional down-regulation of ROCKI/Rho-kinase through an MEK-dependent pathway leads to cytoskeleton disruption in Ras-transformed fibroblasts.

Authors:  Geraldine Pawlak; David M Helfman
Journal:  Mol Biol Cell       Date:  2002-01       Impact factor: 4.138

2.  Opposing roles of the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades in Ras-mediated downregulation of tropomyosin.

Authors:  Janiel M Shields; Heena Mehta; Kevin Pruitt; Channing J Der
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

3.  High molecular weight tropomyosins regulate osteoclast cytoskeletal morphology.

Authors:  Preeyal Kotadiya; Brooke K McMichael; Beth S Lee
Journal:  Bone       Date:  2008-07-12       Impact factor: 4.398

4.  Tropomyosin-2 cDNA lacking the 3' untranslated region riboregulator induces growth inhibition of v-Ki-ras-transformed fibroblasts.

Authors:  R A Janssen; J W Mier
Journal:  Mol Biol Cell       Date:  1997-05       Impact factor: 4.138

5.  Inhibition of anchorage-independent growth of transformed NIH3T3 cells by epithelial protein lost in neoplasm (EPLIN) requires localization of EPLIN to actin cytoskeleton.

Authors:  Yuhong Song; Raymond S Maul; C Sachi Gerbin; David D Chang
Journal:  Mol Biol Cell       Date:  2002-04       Impact factor: 4.138

6.  Caldesmon inhibits nonmuscle cell contractility and interferes with the formation of focal adhesions.

Authors:  D M Helfman; E T Levy; C Berthier; M Shtutman; D Riveline; I Grosheva; A Lachish-Zalait; M Elbaum; A D Bershadsky
Journal:  Mol Biol Cell       Date:  1999-10       Impact factor: 4.138

7.  Protein expression profiling of lens epithelial cells from Prdx6-depleted mice and their vulnerability to UV radiation exposure.

Authors:  Eri Kubo; Nailia Hasanova; Yukie Tanaka; Nigar Fatma; Yoshihiro Takamura; Dhirendra P Singh; Yoshio Akagi
Journal:  Am J Physiol Cell Physiol       Date:  2009-11-04       Impact factor: 4.249

8.  A critical role of tropomyosins in TGF-beta regulation of the actin cytoskeleton and cell motility in epithelial cells.

Authors:  Andrei V Bakin; Alfiya Safina; Cammie Rinehart; Cecilia Daroqui; Huferesh Darbary; David M Helfman
Journal:  Mol Biol Cell       Date:  2004-08-18       Impact factor: 4.138

9.  Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1.

Authors:  J Janke; K Schlüter; B Jandrig; M Theile; K Kölble; W Arnold; E Grinstein; A Schwartz; L Estevéz-Schwarz; P M Schlag; B M Jockusch; S Scherneck
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

10.  Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer.

Authors:  Vid Mlakar; Gasper Berginc; Metka Volavsek; Zdravko Stor; Miran Rems; Damjan Glavac
Journal:  BMC Cancer       Date:  2009-08-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.